{"doi":"10.1016/j.prro.2022.09.007","title":"Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study—An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy","abstract":"PURPOSE: Magnetic resonance (MR)-guided radiation therapy (MRgRT) is a new technique for treatment of localized prostate cancer (PCa). We report the 12-month outcomes for the first PCa patients treated within an international consortium (the MOMENTUM study) on a 1.5T MR-Linac system with ultrahypofractionated radiation therapy. METHODS AND MATERIALS: Patients treated with 5 × 7.25 Gy were identified. Prostate specific antigen-level, physician-reported toxicity (Common Terminology Criteria for Adverse Events [CTCAE]), and patient-reported outcomes (Quality of Life Questionnaire PR25 and Quality of Life Questionnaire C30 questionnaires) were recorded at baseline and at 3, 6, and 12 months of follow-up (FU). Pairwise comparative statistics were conducted to compare outcomes between baseline and FU. RESULTS: The study included 425 patients with localized PCa (11.4% low, 82.0% intermediate, and 6.6% high-risk), and 365, 313, and 186 patients reached 3-, 6-, and 12-months FU, respectively. Median prostate specific antigen level declined significantly to 1.2 ng/mL and 0.1 ng/mL at 12 months FU for the nonandrogen deprivation therapy (ADT) and ADT group, respectively. The peak of genitourinary and gastrointestinal CTCAE toxicity was reported at 3 months FU, with 18.7% and 1.7% grade ≥2, respectively. The QLQ-PR25 questionnaire outcomes showed significant deterioration in urinary domain score at all FU moments, from 8.3 (interquartile range [IQR], 4.1-16.6) at baseline to 12.4 (IQR, 8.3-24.8; P = .005) at 3 months, 12.4 (IQR, 8.3-20.8; P = .018;) at 6 months, and 12.4 (IQR, 8.3-20.8; P = .001) at 12 months. For the non-ADT group, physician- and patient-reported erectile function worsened significantly between baseline and 12 months FU. CONCLUSIONS: Ultrahypofractionated MR-guided radiation therapy for localized PCa using a 1.5T MR-Linac is effective and safe. The peak of CTCAE genitourinary and gastrointestinal toxicity was reported at 3 months FU. Furthermore, for patients without ADT, a significant increase in CTCAE erectile dysfunction was reported at 12 months FU. These data are useful for educating patients on expected outcomes and informing study design of future comparative-effectiveness studies.","journal":"Practical Radiation Oncology","year":2022,"id":240100,"datarank":1.3069542364772309,"base_score":3.8712010109078907,"endowment":3.8712010109078907,"self_citation_contribution":0.5806801516361837,"citation_network_contribution":0.7262740848410472,"self_endowment_contribution":0.5806801516361837,"citer_contribution":0.7262740848410472,"corpus_percentile":null,"corpus_rank":null,"citation_count":47,"citer_count":34,"citers_with_citation_signal":19,"citers_with_endowment":19,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9314,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":867178,"name":"T. Willigenburg","orcid":"0000-0002-4813-6295","position":1,"is_corresponding":false},{"id":262583,"name":"Alison Tree","orcid":"0000-0002-5033-424X","position":2,"is_corresponding":false},{"id":262577,"name":"William A. Hall","orcid":"0000-0001-7017-6755","position":3,"is_corresponding":false},{"id":371591,"name":"Seungtaek Choi","orcid":"0000-0003-3570-0907","position":4,"is_corresponding":false},{"id":654782,"name":"Ananya Choudhury","orcid":"0000-0002-3561-6580","position":5,"is_corresponding":false},{"id":654779,"name":"John P. Christodouleas","orcid":"0000-0001-5061-2038","position":6,"is_corresponding":false},{"id":867987,"name":"Johannes C.J. de Boer","orcid":null,"position":7,"is_corresponding":false},{"id":867988,"name":"Eline N. de Groot-van Breugel","orcid":null,"position":8,"is_corresponding":false},{"id":867179,"name":"Linda G.W. Kerkmeijer","orcid":"0000-0002-7383-2778","position":9,"is_corresponding":false},{"id":858810,"name":"Floris J. Pos","orcid":"0000-0002-0903-4149","position":10,"is_corresponding":false},{"id":867180,"name":"Tine Schytte","orcid":"0000-0002-6705-1561","position":11,"is_corresponding":false},{"id":715187,"name":"Danny Vesprini","orcid":"0000-0001-9714-2782","position":12,"is_corresponding":false},{"id":322458,"name":"Helena M. Verkooijen","orcid":"0000-0001-9480-1623","position":13,"is_corresponding":false},{"id":867989,"name":"Jochem R.N. van der Voort van Zyp","orcid":null,"position":14,"is_corresponding":false},{"id":867177,"name":"Frederik R. Teunissen","orcid":"0000-0002-4184-5195","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:22:46.554789Z","pmid":"36462619","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}